
EMD57033
CAS No. 147527-31-9
EMD57033( —— )
Catalog No. M34074 CAS No. 147527-31-9
EMD57033 is a cardiac troponin C (cTnC) activator, a dominant Ca2+ sensitizer, which functions by binding to cardiac/slow skeletal troponin C heterodimers to promote cardiac contraction.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 483 | Get Quote |
![]() ![]() |
5MG | 715 | Get Quote |
![]() ![]() |
10MG | 938 | Get Quote |
![]() ![]() |
25MG | 1408 | Get Quote |
![]() ![]() |
50MG | 1822 | Get Quote |
![]() ![]() |
100MG | 2250 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameEMD57033
-
NoteResearch use only, not for human use.
-
Brief DescriptionEMD57033 is a cardiac troponin C (cTnC) activator, a dominant Ca2+ sensitizer, which functions by binding to cardiac/slow skeletal troponin C heterodimers to promote cardiac contraction.
-
Description(+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca2+ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function.
-
In Vitro(+)-EMD 57033 (30 μM) recovers the activation and sensitivity of Ca2+ in pig single muscle fibres and reduces VIDD (ventilator-induced diaphragm muscle fibre dysfunction) of .(+)-EMD 57033 (5.0-5.8 μM; 10-15 min) significantly increases the coronary blood flow and myocardial V?o2 (O2?consumption) in both 100 bpm and 150 bpm heart rates of rabbit heart, with a [Ca2+]0 concentration-dependent manner ([Ca2+]0=1.0 or 2.5 mM).(+)-EMD 57033 (5.0-5.8 μM; 10-15 min) increases left ventricular?(LV) end-diastolic pressure and prolongs relaxation.
-
In Vivo(+)-EMD 57033 (0.4 or 0.8 mg/kg/min; i.v.drip; over than 20 min) enhances contractility and achieves Ca2+ sensitization in intact failing hearts at substantial energetic savings and without compromise of diastolic function in dogs.Animal Model:Mongrel dogs implanted with a micromanometer in left ventricle (LV) at the apex via lateral thoracotomy Dosage:0.4 or 0.8 mg/kg/min Administration:Intravenous drip; infused over 20 minutes Result:Enhanced contractility at both doses, with similar changes in CON (conscious dogs) and HF (heart failure dogs) hearts. Decreased the end-diastolic pressure (EDP) and lowered arterial load or preload at 0.8 mg/kg/min.
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetCarbonic Anhydrase
-
RecptorCarbonic Anhydrase | Calcium Channel
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number147527-31-9
-
Formula Weight425.5
-
Molecular FormulaC22H23N3O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C1=CC(OC)=C(C=C1)OC)N2C3=CC=C(C([C@H](S4)C)=NNC4=O)C=C3CCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wang X, et al. Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033. J Biol Chem. 2001 Jul 6;276(27):25456-66. ?
molnova catalog



related products
-
Girentuximab
Girentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPUP).
-
Levosimendan
Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides treatment for heart failure.
-
Tioxolone
Tioxolone is a metalloenzyme carbonic anhydrase I inhibitor.